Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

722117

registered interest
date	18/04/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to encourage innovative stem cell and umbilical cord treatments for liver disease.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	71132
answer	answer is ministerial correction date of answer 26/04/2017 answer text <p>The Government continues to support research through a range of funding agencies into the therapeutic use of stem cells. Over 80 patients have been recruited to a clinical trial to test the potential use of stem cells to treat liver disease. The results of this trial will only be available when the follow-up phase of the study has been completed. Before making this type of treatment available through the National Health Service it will be necessary to demonstrate that the treatment is both safe and effective and this is likely to involve further larger clinical trials.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 26/04/2017 09:22:39 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4131 label Biography information for Jim Shannon

675194

registered interest
date	18/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what was the incidence of non-alcoholic fatty liver disease in humans in (1) 1990, (2) 1995, (3) 2005, and (4) 2015.
tabling member printed	The Countess of Mar
uin	HL4759
answer	answer is ministerial correction date of answer 27/01/2017 answer text <p>The data is not available in the format requested.</p> answering member printed Lord O'Shaughnessy question first answered 27/01/2017 12:09:25 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1861 label Biography information for The Countess of Mar

606809

registered interest
date	20/10/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to increase the provision of (a) medical and (b) nursing training in hepatology.
tabling member constituency	Knowsley
tabling member printed	Mr George Howarth
uin	49658
answer	answer is ministerial correction date of answer 26/10/2016 answer text <p>It is the responsibility of the professional regulators such as the General Medical Council or the Nursing and Midwifery Council (NMC) to set the standards and outcomes for education and training and approve training curricula to ensure newly qualified healthcare professionals are equipped with the knowledge, skills and attitudes to provide high quality patient care.</p><p> </p><p>Hepatology is a medical sub-specialty of gastroenterology. In Health Education England’s 2016/17 Workforce Plan for England, there are 450 training commissions proposed for gastroenterology, an increase from 431 in 2015/16.</p><p>Whilst the NMC does not recognise hepatology in its standards for specialist education and practice, the Royal College of Nursing has written a comprehensive competence framework which outlines the training, skills and competence required to develop and maintain a special interest in hepatology:</p><p><a href="https://www2.rcn.org.uk/__data/assets/pdf_file/0004/641425/004-983_WEB.pdf" target="_blank">https://www2.rcn.org.uk/__data/assets/pdf_file/0004/641425/004-983_WEB.pdf</a></p> answering member constituency Ludlow answering member printed Mr Philip Dunne question first answered 26/10/2016 14:56:00 answering member 1542 label Biography information for Philip Dunne
tabling member	481 label Biography information for Sir George Howarth

577540

registered interest
date	07/09/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects Public Health England to publish the National Liver Strategy Framework.
tabling member constituency	Heywood and Middleton
tabling member printed	Liz McInnes
uin	45448
answer	answer is ministerial correction date of answer 12/09/2016 answer text <p>Public Health England (PHE) has a wide range of work to tackle liver disease. This includes monitoring deaths from liver disease and its risk factors, publishing Local Authority Liver Disease Profiles and updating the Atlas of Variation on Liver Disease. The Atlas of Variation will inform the development of the PHE Liver Disease Framework, therefore publication is likely to take place after the update is completed this winter.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 12/09/2016 13:11:00 answering member 4080 label Biography information for David Mowat
tabling member	4342 label Biography information for Liz McInnes

577541

registered interest
date	07/09/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the annual cost of care is for a person with (a) decompensated cirrhosis of the liver and (b) hepatocellular carcinoma.
tabling member constituency	Heywood and Middleton
tabling member printed	Liz McInnes
uin	45449
answer	answer is ministerial correction date of answer 12/09/2016 answer text <p>The information is not available in the format requested. Such information as is available is shown in the table below and is from reference costs, which are the average unit cost to National Health Service trusts and foundation trusts of providing defined services in a given financial year. Reference costs are published annually, with most recently available data being for 2014-15.</p><p> </p><p>Reference costs for acute care are collected by healthcare resource group (HRG), which are standard groupings of clinically similar treatments that consume similar levels of healthcare resource. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapters GC and PG describe hepatobiliary and pancreatic system disorders for adults and children respectively. The average costs in the following table will therefore include the costs to NHS hospitals of treating decompensated cirrhosis of the liver and hepatocellular carcinoma, as well as the costs of other related disorders.</p><p> </p><p>These costs do not include high cost drugs, or treatment in outpatient or other settings outside of hospital. They reflect the costs of a single episode of care under one consultant for a patient admitted to hospital for either elective or non-elective treatment. Patients admitted to hospital may have multiple episodes of care and each one of these episodes will be recorded separately.</p><p> </p><p>Total cost to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15</p><table><tbody><tr><td><p> </p></td><td><p>Average cost per Finished Consultant Episode (£)</p></td></tr><tr><td><p>Malignant, Hepatobiliary or Pancreatic Disorders<sup>1</sup></p></td><td><p>1,984</p></td></tr><tr><td><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders<sup>2</sup></p></td><td><p>1,751</p></td></tr><tr><td><p>Paediatric, Hepatobiliary or Pancreatic Disorders<sup>3</sup></p></td><td><p>2,344</p></td></tr></tbody></table><p><em>Source: </em>Reference costs, Department of Health</p><p> </p><p><em>Notes:</em></p><p>1. The following HRGs are included in the table:</p><p>GC12C Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions</p><p>GC12D Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 5+</p><p>GC12E Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 2-4</p><p>GC12F Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-1</p><p>GC12G Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 6+</p><p>GC12H Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 3-5</p><p>GC12J Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 1-2</p><p>GC12K Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0</p><p>2. GC17A Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+</p><p>GC17B Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8</p><p>GC17C Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3</p><p>GC17D Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+</p><p>GC17E Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8</p><p>GC17F Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3</p><p>GC17G Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+</p><p>GC17H Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7</p><p>GC17J Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4</p><p>GC17K Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1</p><p>3. PG71A Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 2+</p><p>PG71B Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 1</p><p>PG71C Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 0</p><p>4. These HRGs are common groupings of the ICD-10 codes used to count the number of finished admission episodes with a primary or secondary diagnosis of hepatocellular carcinoma or decompensated cirrhosis. They also include other ICD-10 codes</p><p>5. For each HRG or other currency in the reference cost collection, NHS hospital trusts submit a unit cost and amount of activity undertaken.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 12/09/2016 13:18:01 answering member 4080 label Biography information for David Mowat
tabling member	4342 label Biography information for Liz McInnes

541043

registered interest
date	20/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to improve (a) expertise and (b) facilities in primary care to strengthen (i) detection of early liver disease and (ii) treatment for liver disease.
tabling member constituency	Stockton North
tabling member printed	Alex Cunningham
uin	43645
answer	answer is ministerial correction date of answer 05/09/2016 answer text <p>I understand that the British Liver Trust is working in partnership with the Royal College of General Practitioners on a three year programme to make liver disease a clinical priority for primary care. This is aimed at improving awareness and understanding of liver disease as well as treatment amongst those working in primary care.</p><p> </p><p>Public Health England is currently developing a framework to tackle liver disease. This will include the action that needs to be taken across the health and care system, including in primary care, to prevent and better manage liver disease.</p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 43644 question first answered 05/09/2016 08:53:18 answering member 4080 label Biography information for David Mowat
tabling member	4122 label Biography information for Alex Cunningham

541044

registered interest
date	20/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment has been made of the causes of regional variation in liver disease outcomes in England.
tabling member constituency	Stockton North
tabling member printed	Alex Cunningham
uin	43646
answer	answer is ministerial correction date of answer 05/09/2016 answer text <p>Public Health England (PHE) has developed and publishes liver disease profiles for all local authorities in England. The profiles provide support to local areas to understand liver disease and its risk factors in their area. They present key local statistics and highlight questions to ask locally about current action to prevent liver disease.</p><p> </p><p>The Local Authority Liver Disease Profiles demonstrate geographical variation in the main risk factors: alcohol, obesity, hepatitis B and C which explain some of the regional and local authority variations in outcome. Experts at PHE in these three areas regularly review these statistics and the evidence for intervention. The profiles demonstrate that there are widespread opportunities to reduce mortality from liver disease prevention.</p><p> </p><p>PHE is also updating the 2013 NHS Atlas of Variation in Healthcare for People with Liver Disease highlighting variations in risk factors, health services and outcomes.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 05/09/2016 08:52:35 answering member 4080 label Biography information for David Mowat
tabling member	4122 label Biography information for Alex Cunningham

516846

registered interest
date	29/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions officials in his Department have had with Public Health England on the potential effects of minimum unit pricing of alcohol on liver disease health outcomes in England.
tabling member constituency	Dewsbury
tabling member printed	Paula Sherriff
uin	36154
answer	answer is ministerial correction date of answer 10/05/2016 answer text <p>There have been no meetings specifically to discuss the potential effects of minimum unit pricing on liver disease health outcomes in England.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/05/2016 16:24:16 answering member 3918 label Biography information for Jane Ellison
tabling member	4426 label Biography information for Paula Sherriff

506581

registered interest
date	08/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average cost of treating a patient with (a) hepatitis C, (b) cirrhosis and (c) hepatitis C and cirrhosis has been in the last 12 months for which figures are available.
tabling member constituency	Corby
tabling member printed	Tom Pursglove
uin	32899
answer	answer is ministerial correction date of answer 18/04/2016 answer text <p><strong> </strong></p><p>The information is not available in the format requested. Such information as is available is shown in the table below and is from reference costs, which are the average unit cost to National Health Service trusts and foundation trusts of providing defined services in a given financial year. Reference costs are published annually, with most recently available data being for 2014-15.</p><p> </p><p>Reference costs for acute care are collected by healthcare resource group (HRG), which are standard groupings of clinically similar treatments that consume similar levels of healthcare resource. HRGs are organised by chapters and sub-chapters, representing different body systems, and HRG sub-chapters GC and PG describe hepatobiliary and pancreatic system disorders for adults and children respectively. The average costs in the following table will therefore include the costs to NHS hospitals of treating hepatitis C and cirrhosis, as well as the costs of other related disorders.</p><p> </p><p>These costs do not include high cost drugs, or treatment in outpatient or other settings outside of hospital. They reflect the costs of a single episode of care under one consultant for a patient admitted to hospital. Patients admitted to hospital may have multiple episodes of care and each one of these episodes will be recorded separately.</p><p> </p><p> </p><p>Table: Average cost to NHS hospitals of treating hepatobiliary and pancreatic system disorders, 2014-15 (excluding high cost drugs, or treatment in outpatient or other settings outside of hospital)</p><table><tbody><tr><td><p> </p></td><td><p>Average cost per unit of activity (£)</p></td></tr><tr><td><p>Non-Malignant, Hepatobiliary or Pancreatic Disorders</p></td><td><p>1,751</p></td></tr><tr><td><p>Paediatric, Hepatobiliary or Pancreatic Disorders</p></td><td><p>2,344</p></td></tr></tbody></table><p><em>Source: </em>Reference costs, Department of Health</p><p> </p><p><em>Notes:</em></p><ol><li>The following HRGs are included in the table:</li></ol><p>GC17A Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 9+</p><p>GC17B Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 4-8</p><p>GC17C Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Multiple Interventions, with CC Score 0-3</p><p>GC17D Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 9+</p><p>GC17E Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 4-8</p><p>GC17F Non-Malignant, Hepatobiliary or Pancreatic Disorders, with Single Intervention, with CC Score 0-3</p><p>GC17G Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 8+</p><p>GC17H Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 5-7</p><p>GC17J Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 2-4</p><p>GC17K Non-Malignant, Hepatobiliary or Pancreatic Disorders, without Interventions, with CC Score 0-1</p><p>PG71A Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 2+</p><p>PG71B Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 1</p><p>PG71C Paediatric, Hepatobiliary or Pancreatic Disorders, with CC Score 0</p><ol start="2"><li>These HRGs are common groupings of the ICD-10 codes used to count the number of finished admission episodes with a primary or secondary diagnosis of hepatitis C or cirrhosis. They also include other ICD-10 codes.</li><li>For each HRG or other currency in the reference cost collection, NHS hospital trusts submit a unit cost and amount of activity undertaken.</li></ol><p><strong> </strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 18/04/2016 16:43:27 answering member 3918 label Biography information for Jane Ellison
tabling member	4369 label Biography information for Tom Pursglove

456168

registered interest
date	29/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many hospital admissions due to liver disease there were in (a) England and (b) each parliamentary constituency in the last year for which figures are available.
tabling member constituency	Salisbury
tabling member printed	John Glen
uin	28830
answer	answer is ministerial correction date of answer 08/03/2016 answer text <p>The information requested is in the attached table.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/03/2016 16:43:04 answering member 3918 label Biography information for Jane Ellison attachment 1 file name PQ28830 TABLE.xlsx title Finished admission episodes liver disease
tabling member	4051 label Biography information for John Glen